I. what is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?
Urata, Y.; Satouchi, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 931-934
2015
ISSN/ISBN: 0385-0684 PMID: 26353389 Document Number: 682913
Document emailed within 1 workday
Related Documents
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
Zhang, J.Q.; Xu, F.; Xu, X.L.; Zhou, H.C. 2017: Erlotinib in the treatment of small cell lung cancer with EGFR mutation: a case report Zhonghua Zhong Liu Za Zhi 39(9): 717-719
Saxena, A.; Nagasaka, M.; Li, Z.; Becker, D.J.; Levy, B.P. 2014: Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer Oncology 28(6): 526; 528 530, 534
Yang, B.; Zheng, D.; Zeng, Υa.; Qin, A.; Gao, J.; Yu, G. 2018: Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(4): 1077-1081
Shi, Y. 2015: The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version) Zhonghua Zhong Liu Za Zhi 37(10): 796-799
Dong, Q.-g.; Han, B.-h.; Huang, J.-s.; Yang, L.-m.; Huang, J.; Zhao, C.-y.; Lu, L.-q. 2006: Analysis of EGFR mutations in 176 cases of non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 28(9): 686-690
Forde, P.M.; Ettinger, D.S. 2015: Managing acquired resistance in EGFR-mutated non-small cell lung cancer Clinical Advances in Hematology and Oncology: H&o 13(8): 528-532
Dahse, R.; Berndt, A.; Kosmehl, H. 2008: PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer Anticancer Research 28(4b): 2265-2270
Li, Z.; Zhang, L-jun.; Wang, W-ping.; Guo, K.; Shao, J-yong.; Rong, T-hua. 2011: Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 33(9): 666-670
Hirano, S.; Takeda, Y.; Hiraishi, Y.; Higashino, M.; Nakamichi, S.; Ishii, S.; Naka, G.; Iikura, M.; Izumi, S.; Sugiyama, H.; Kobayashi, N. 2012: Efficacy of combination therapy with EGFR-TKi and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKi Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 213-219
Xu, C.-a.; Su, H.; Liu, J.-l.; Li, L.; Zou, H.-w. 2011: Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor Zhonghua Zhong Liu Za Zhi 33(6): 436-441
Gombos, Z.; Danihel, L.; Puttaswamy, K.; Brose, M. 2010: A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung Bratislavske Lekarske Listy 111(7): 365-368
Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
El Hamdani, W.; Amrani, M.; Attaleb, M.; Laantri, N.; Ennaji, M.M.; Khyatti, M.; El Mzibri, M. 2010: EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women Cellular and Molecular Biology 56 Suppl: Ol1373-Ol1384
Zhang, R.; Li, Y.; Chen, Y.; Liu, X.; Wang, Z.; Sun, H.; Zheng, Y.; Ding, Z.; Lan, L.; Li, M.; Qin, J.; Chen, X. 2015: Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer Zhonghua Yi Xue Za Zhi 95(47): 3839-3842
Osera, S.; Shitara, K. 2013: II. which is the better choice for second- line treatment?; BEV or anti-EGFR after BEV treatment in patients with unresectable wild type K-ras colon cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(11): 1459
Cirillo, M.; Lombardi, C.; Chiricone, D.; Bilancio, G.; Marcarelli, F.; De Santo, N.G. 2008: Early identification of kidney disease by eGFR: what is the prevalence of eGFR in the population? Journal of Nephrology 21(Suppl 13): S102-S106
Yano, S.; Kondo, K.; Yamaguchi, M.; Richmond, G.; Hutchison, M.; Wakeling, A.; Averbuch, S.; Wadsworth, P. 2003: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Research 23(5a): 3639-3650